Investment Thesis
Annexon is a pre-revenue biopharmaceutical company with severe cash burn ($140.4M operating cash outflow) and no commercial revenue, indicating the company is entirely dependent on external financing and successful clinical trial outcomes. The company's cash runway of approximately 1 year at current burn rates creates significant existential risk, and negative ROE of -98.1% reflects massive shareholder value destruction despite adequate liquidity from remaining cash reserves.
ANNX Strengths
- Strong liquidity position with $139.4M cash and 4.42x current ratio provides near-term operational flexibility
- Zero long-term debt reduces financial leverage risk and interest burden
- Adequate stockholders' equity of $161.4M provides some balance sheet cushion for development phase operations
ANNX Risks
- No revenue generation with pre-commercial pipeline creates zero near-term monetization pathway
- Unsustainable cash burn of $140.4M annually will exhaust cash reserves within 12 months without additional financing
- Severe negative returns (ROE -98.1%, ROA -69.1%) indicate clinical development failures or capital inefficiency requiring future dilutive financing
- High insider trading activity (18 Form 4 filings in 90 days) warrants investigation for potential negative signaling
Key Metrics to Watch
- Operating cash flow trend and cash runway remaining before next financing event
- Clinical trial advancement and regulatory milestones for pipeline assets
- Capital raise activity, dilution, and per-share burn metrics
ANNX Financial Metrics
ANNX Profitability Ratios
ANNX Balance Sheet & Liquidity
ANNX 5-Year Financial Trend
5-Year Trend Summary: Annexon, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.77 indicates the company is currently unprofitable.
ANNX Growth Metrics (YoY)
ANNX Capital Allocation
ANNX SEC Filings
Access official SEC EDGAR filings for Annexon, Inc. (CIK: 0001528115)